ANYL 238 |
| Ischemia markers for evaluating acute coronary syndrome (ACS) patients are essential for the early diagnosis and risk stratification of chest pain patients presenting to the emergency department. Our approach to biomarker discovery for myocardial ischemia centers on in-depth analysis of temporal serum samples obtained from patients undergoing cardiac catherization and/or angioplasty in which balloon inflation induces a timed ischemic event. In-depth proteomic analysis of serum samples obtained during the course of the evolving ischemia allows differentiation between potential ischemic biomarkers from traditional cellular necrosis markers (TnI). Serial serum samples were obtained under strict collection protocols and each patient's serum was partitioned into an HSA-enriched and immunoglobin/HSAdepleted fractions. The immunoglobulin/HAS depleted fractions were analyzed using 2DE and various LC techniques. Intact mass is determined by MALDI TOF MS for the differential LC fractions and used for validation of protein identification and post translational modifications. The detection of skeletal and cardiac muscle cellular proteins and cytokines indicated that the combined protein separation methods allow proteome coverage of 10e8. The protein composition of the serum changed over time in patients with evolving ischemia and was startling different from the healthy and disease controls. |
|
New Directions and New Techniques in Separation Science and Biomarker Discovery
1:30 PM-4:50 PM, Tuesday, 12 September 2006 Moscone Center -- Room 130, Oral
Division of Analytical Chemistry |